Delivery of Medical Microdevice Prototypes and Development of Mass-Production Processes
First written in FY2018. 5 of 7 entries say "Advanced", first in FY2019. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In the medical-device field, the team that developed the injection system ZELOSTAT, which minimizes medication waste, received the Excellence Award in the Monozukuri Nippon Grand Award. For the multi-needle product Quatron, which has been sold for several years, the company is developing a next-generation model that combines substantial cost reductions with improved operability and aims to launch it during its 64th fiscal year.」
The company disclosed the award received by the ZELOSTAT development team, development of the next-generation Quatron, and the provision of microneedle samples to research institutions in Japan and overseas. - FY2024AdvancedAnnual report
「In the medical-device field, with a subsidy from the Ministry of Economy, Trade and Industry, we developed a needle with low medication waste suitable for vaccine injections and other applications and began sales in Europe in February 2024. The product lineup includes a certified injection needle with the smallest diameter, at 0.16 mm, and has received high praise from various countries. Going forward, we will file a domestic regulatory application and aim to obtain approval during the next fiscal year.」
The company disclosed the start of sales in Europe in February 2024 for needles with low medication waste, a 0.16 mm-diameter product in the lineup, and plans to file a domestic regulatory application and obtain approval during the next fiscal year. - FY2022AdvancedAnnual report
「We are accelerating the development of needles and syringes with low dead space, or low medication waste, which are effective for vaccine injections and other applications, and aim to begin sales during the next fiscal year.」
As medical products following Quatron, the company is accelerating development of needles and syringes that reduce medication waste and has set a target of beginning sales during the next fiscal year. - FY2021AdvancedAnnual report
「For the single-use injection needle (Quatron), sales of which began in the previous fiscal year, the Company developed proprietary automated assembly equipment to expand sales. Mass production is scheduled to begin around autumn 2021.」
For medical microdevices, the company developed automated assembly equipment as an expansion initiative following the start of sales in Europe and has progressed to the stage of planning for mass-production operations. - FY2020AchievedAnnual report
「Development of the newly developed single-use injection needle Quatron (registered trademark) has been completed, and the product was launched in Europe in early 2020. Before this, at the end of 2019, we obtained ISO 13485 certification for a medical-device quality management system and EC certification, and registered as a domestic medical-device manufacturer.」
The company disclosed specific milestones for its medical products, from completion of development and acquisition of ISO 13485 and EC certification to registration as a domestic manufacturer and launch in Europe. - FY2019AdvancedAnnual report
「The New Business Division is pursuing initiatives to commercialize new products in the medical field.」
In the medical field, the company has progressed from prototype deliveries and mass-production process development to initiatives aimed at commercializing new products. - FY2018First statedAnnual report
「For medical microdevices using ultra-fine molding technology, we began delivering prototypes and proceeded with the development of mass-production processes.」
The company disclosed for the first time the start of prototype deliveries and the development of mass-production processes for medical microdevices using ultra-fine molding technology.